Schroder Investment Management Group Makes New $4.89 Million Investment in Zymeworks Inc. (NYSE:ZYME)

Schroder Investment Management Group acquired a new stake in shares of Zymeworks Inc. (NYSE:ZYME) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 337,161 shares of the company’s stock, valued at approximately $4,892,000. Schroder Investment Management Group owned approximately 0.49% of Zymeworks as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZYME. Charles Schwab Investment Management Inc. increased its position in shares of Zymeworks by 0.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 132,798 shares of the company’s stock worth $1,667,000 after acquiring an additional 650 shares in the last quarter. FMR LLC boosted its stake in Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after purchasing an additional 1,525 shares during the last quarter. Stifel Financial Corp increased its holdings in Zymeworks by 2.1% during the 3rd quarter. Stifel Financial Corp now owns 73,654 shares of the company’s stock worth $924,000 after purchasing an additional 1,540 shares in the last quarter. State Street Corp raised its stake in shares of Zymeworks by 6.1% in the third quarter. State Street Corp now owns 1,171,777 shares of the company’s stock worth $14,706,000 after purchasing an additional 67,401 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Zymeworks by 27.3% in the third quarter. Jane Street Group LLC now owns 80,326 shares of the company’s stock valued at $1,008,000 after purchasing an additional 17,205 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Insider Transactions at Zymeworks

In other Zymeworks news, EVP Jeffrey T. L. Smith sold 11,110 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $165,761.20. Following the completion of the transaction, the executive vice president now owns 8,890 shares in the company, valued at $132,638.80. This trade represents a 55.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock in a transaction dated Wednesday, January 8th. The stock was acquired at an average price of $14.07 per share, with a total value of $295,765.47. Following the purchase, the director now directly owns 15,206,980 shares of the company’s stock, valued at approximately $213,962,208.60. This represents a 0.14 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 1,437,977 shares of company stock worth $17,906,778 and sold 89,601 shares worth $1,336,847. 1.92% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms recently commented on ZYME. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target for the company in a research report on Monday, December 16th. Lifesci Capital began coverage on shares of Zymeworks in a report on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 target price for the company. Wells Fargo & Company raised their price target on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research report on Thursday, December 19th. HC Wainwright upped their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday, March 10th. Finally, Citigroup lifted their target price on shares of Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, March 7th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Zymeworks Stock Performance

NYSE ZYME opened at $10.95 on Friday. The company has a market capitalization of $761.87 million, a PE ratio of -7.30 and a beta of 1.18. Zymeworks Inc. has a 52-week low of $7.97 and a 52-week high of $17.70. The company has a 50-day simple moving average of $13.31 and a 200 day simple moving average of $13.70.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.